Trial Profile
Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population: A Phase II, Randomized, Placebo-controlled, Observer-blinded Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Sponsors BioNTech
- 09 May 2022 Status changed from active, no longer recruiting to completed.
- 02 May 2022 Planned End Date changed from 30 Apr 2022 to 30 Oct 2022.
- 02 May 2022 Planned primary completion date changed from 30 Apr 2022 to 30 Sep 2022.